Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer.
PURPOSE Conventional medicine has had little to offer patients with inoperable pancreatic adenocarcinoma; thus, many patients seek alternative treatments. The National Cancer Institute, in 1998, sponsored a randomized, phase III, controlled trial of proteolytic enzyme therapy versus chemotherapy. Because most eligible patients refused random assignment, the trial was changed in 2001 to a controlled, observational study. METHODS All patients were seen by one of the investigators at Columbia University, and patients who received enzyme therapy were seen by the participating alternative practitioner. Of 55 patients who had inoperable pancreatic cancer, 23 elected gemcitabine-based chemotherapy, and 32 elected enzyme treatment, which included pancreatic enzymes, nutritional supplements, detoxification, and an organic diet. Primary and secondary outcomes were overall survival and quality of life, respectively. Results At enrollment, the treatment groups had no statistically significant differences in patient characteristics, pathology, quality of life, or clinically meaningful laboratory values. Kaplan-Meier analysis found a 9.7-month difference in median survival between the chemotherapy group (median survival, 14 months) and enzyme treatment groups (median survival, 4.3 months) and found an adjusted-mortality hazard ratio of the enzyme group compared with the chemotherapy group of 6.96 (P < .001). At 1 year, 56% of chemotherapy-group patients were alive, and 16% of enzyme-therapy patients were alive. The quality of life ratings were better in the chemotherapy group than in the enzyme-treated group (P < .01). CONCLUSION Among patients who have pancreatic cancer, those who chose gemcitabine-based chemotherapy survived more than three times as long (14.0 v 4.3 months) and had better quality of life than those who chose proteolytic enzyme treatment.
Chabot
John A
JA
Columbia University Mailman School of Public Health, 722 W 168th St, Rm 734, New York, NY 10032, USA.
Tsai
Wei-Yann
WY
Fine
Robert L
RL
Chen
Chunxia
C
Kumah
Carolyn K
CK
Antman
Karen A
KA
Grann
Victor R
VR
D000230:Adenocarcinoma / Q000178:diet therapy / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000529:Complementary Therapies / Q000009:adverse effects; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D019587:Dietary Supplements / Q000009:adverse effects; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000178:diet therapy / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D010447:Peptide Hydrolases / Q000009:adverse effects / Q000627:therapeutic use*; D016016:Proportional Hazards Models; D011788:Quality of Life; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D010447:Peptide Hydrolases; D000093542:Gemcitabine
Semin Oncol. 2005 Aug;32(4 Suppl 6):S1-3
16143160
Zhong Xi Yi Jie He Xue Bao. 2006 Sep;4(5):455-66
16965737
N Engl J Med. 2000 Jun 22;342(25):1907-9
10861329
J Natl Cancer Inst. 2002 Sep 4;94(17):1275-81
12208892
Clin Adv Hematol Oncol. 2003 Jul;1(7):430-4
16258429
J Clin Oncol. 2001 Sep 15;19(18 Suppl):55S-60S
11560974
N Engl J Med. 2000 Jun 22;342(25):1887-92
10861325
Biometrics. 1985 Mar;41(1):103-16
4005368
Nutr Cancer. 1999;33(2):117-24
10368805
J Clin Oncol. 1997 Jun;15(6):2403-13
9196156
J Clin Oncol. 1995 Mar;13(3):748-55
7884435
Clin Cancer Res. 2002 May;8(5):935-42
12006504
Cancer Chemother Pharmacol. 2008 Jan;61(1):167-75
17440727
Ann Intern Med. 1997 Oct 15;127(8 Pt 2):757-63
9382394
JAMA. 2005 Feb 23;293(8):1001-3
15728172
J Clin Oncol. 2003 Sep 15;21(18):3402-8
12885837
J Surg Res. 2004 Mar;117(1):144-53
15013725
Semin Pediatr Infect Dis. 2004 Jan;15(1):52-7
15175995
Oncologist. 2008 May;13(5):562-76
18515741
JAMA. 2005 Feb 23;293(8):970-8
15728168
Ann Intern Med. 1950 Jan;32(1):80-115, illust
15404129
J Clin Oncol. 2007 May 20;25(15):1960-6
17452677
Integr Cancer Ther. 2007 Sep;6(3):208-34
17761635
JAMA. 2004 Mar 3;291(9):1092-9
14996778
Emerg Themes Epidemiol. 2005 Sep 01;2:8
16137327
J Natl Compr Canc Netw. 2005 Sep;3(5):627-36
16194454
J Clin Oncol. 2000 Feb;18(3):668-83
10653883
Palliat Support Care. 2003 Sep;1(3):267-73
16594427
N Engl J Med. 1994 Apr 14;330(15):1029-35
8127329
J Clin Oncol. 2005 May 20;23(15):3509-16
15908661
Surg Oncol Clin N Am. 2004 Oct;13(4):711-35, x
15350944
Support Care Cancer. 2005 Oct;13(10):806-11
15711946
BMC Complement Altern Med. 2007 Aug 04;7:25
17683580
Spine (Phila Pa 1976). 2003 Oct 1;28(19):2268-75
14520043
J Clin Oncol. 2000 Nov 1;18(21):3595-603
11054432
Qual Life Res. 2002 May;11(3):207-21
12074259